Maze Therapeutics (NASDAQ:MAZE) Given New $36.00 Price Target at Wedbush

Maze Therapeutics (NASDAQ:MAZE) had its price objective upped by Wedbush from $35.00 to $36.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush’s price target points to a potential upside of 28.16% from the company’s previous close.

Several other brokerages also recently issued reports on MAZE. Guggenheim increased their price target on Maze Therapeutics from $19.00 to $34.00 and gave the company a “buy” rating in a report on Monday, September 15th. JPMorgan Chase & Co. boosted their price target on Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a research report on Monday, September 29th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Maze Therapeutics in a report on Thursday, September 18th. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Wednesday, October 8th. Finally, BTIG Research raised their price target on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a report on Friday, September 12th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Maze Therapeutics currently has a consensus rating of “Buy” and an average price target of $37.00.

Maze Therapeutics Trading Down 5.2%

Shares of NASDAQ MAZE traded down $1.54 during midday trading on Friday, reaching $28.09. 78,871 shares of the stock were exchanged, compared to its average volume of 299,937. The company has a market capitalization of $1.23 billion and a P/E ratio of -1.39. Maze Therapeutics has a 52-week low of $6.71 and a 52-week high of $34.29. The stock has a 50 day moving average price of $25.57 and a 200-day moving average price of $17.07.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Insider Activity

In related news, Director Richard H. Scheller sold 20,744 shares of the firm’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Hedge Funds Weigh In On Maze Therapeutics

A number of large investors have recently bought and sold shares of MAZE. New York State Common Retirement Fund bought a new stake in shares of Maze Therapeutics in the 1st quarter worth approximately $25,000. CWM LLC bought a new stake in Maze Therapeutics in the second quarter valued at $28,000. Corebridge Financial Inc. acquired a new position in shares of Maze Therapeutics during the first quarter valued at $48,000. Legal & General Group Plc grew its position in shares of Maze Therapeutics by 387.0% during the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after acquiring an additional 3,371 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Maze Therapeutics by 452.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock worth $57,000 after acquiring an additional 3,774 shares during the period.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.